ArticleJournal of managed care & specialty pharmacy2025
Cost-effectiveness of cemiplimab plus chemotherapy vs pembrolizumab plus chemotherapy as first-line treatment for advanced non-small cell lung cancer.
Xiangzhong Xue et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.